Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
https://www.zacks.com/stock/news/2203216/coherus-chrs-stock-rallies-on-fda-nod-for-udenyca-onbody?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2203216
Dec 28, 2023 - The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.
0
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmy-s-krtx-and-ryzb-acquisition-cytk-surges-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2203052
Dec 28, 2023 - Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
Can Dogs of the Dow ETFs Snap Losing Trend in 2024?
https://www.zacks.com/stock/news/2200407/can-dogs-of-the-dow-etfs-snap-losing-trend-in-2024?cid=CS-ZC-FT-etf_news_and_commentary-2200407
Dec 20, 2023 - The Dogs of the Dow underperformed the broader market in 2023. However, with the Fed likely to cut rates in 2024, can these dividend dogs roar next year?
0
Amgen (AMGN) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2199629/amgen-amgn-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2199629
Dec 18, 2023 - Amgen (AMGN) reachead $275.48 at the closing of the latest trading day, reflecting a +0.01% change compared to its last close.
0
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
https://www.zacks.com/stock/news/2197836/amgen-s-amgn-tarlatamab-bla-gets-fda-priority-tag-for-sclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197836
Dec 14, 2023 - Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.
0
1 Biotech Stock That Could Be the Next Amgen
https://www.fool.com/investing/2023/12/13/1-biotech-stock-that-could-be-the-next-amgen/?source=iedfolrf0000001
Dec 13, 2023 - The emergence of genomic medicine as a viable modality could transform this midcap biotech into the next Amgen.
0